B. Riley Has Negative Estimate for InfuSystem Q1 Earnings

InfuSystem Holdings, Inc. (NYSE:INFU) – Equities researchers at B. Riley cut their Q1 2025 EPS estimates for InfuSystem in a research note issued to investors on Tuesday, March 4th. B. Riley analyst K. Bauser now anticipates that the company will post earnings of ($0.03) per share for the quarter, down from their prior forecast of $0.04. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem’s Q4 2025 earnings at $0.12 EPS.

Separately, StockNews.com downgraded shares of InfuSystem from a “strong-buy” rating to a “buy” rating in a research note on Thursday.

InfuSystem Stock Up 0.3 %

INFU opened at $6.25 on Friday. InfuSystem has a fifty-two week low of $5.74 and a fifty-two week high of $9.97. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59. The firm’s fifty day moving average price is $7.96 and its two-hundred day moving average price is $7.60. The company has a market capitalization of $132.90 million, a P/E ratio of 104.18 and a beta of 1.75.

Institutional Investors Weigh In On InfuSystem

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its holdings in shares of InfuSystem by 66.4% during the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after acquiring an additional 1,626 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of InfuSystem by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,286 shares of the company’s stock valued at $78,000 after acquiring an additional 3,165 shares during the period. Legato Capital Management LLC bought a new position in shares of InfuSystem during the fourth quarter valued at $85,000. Summit Global Investments bought a new position in shares of InfuSystem during the fourth quarter valued at $86,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of InfuSystem during the third quarter valued at $87,000. Institutional investors and hedge funds own 71.13% of the company’s stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.